In breast cancer cell lines, it was shown that Cycloguanil and its most promising analogue, NSC127159, were shown to inhibit Dihydrofolate reductase (DHFR), an established anti-cancer drug target whose inhibition disrupts folate metabolism and STAT3-dependent gene expression. The gene discussed is STAT3; the disease is cancer.